Of all the life-threatening conditions hospitals battle on a daily basis, sepsis is a particularly fickle beast. Despite the difficulties associated with diagnosing this complication, healthcare ...

A long-awaited study of septic shock treatments has found that expensive and risky parts of a widely accepted resuscitation protocol now in place in many hospitals do not improve outcomes when ...

Sepsis is the body’s extreme reaction to an infection. It causes 11 million deaths annually and is a global health priority affecting 55 million patients worldwide annually. Treatment for sepsis ...

Sepsis, a common and potentially deadly complication to an infection, is the leading cause of death in U.S. hospitals, accounting for 35% of in-hospital deaths. But as many as 87% of sepsis cases ...

Today, nearly all patients with septic shock receive the same first-line therapy. However, early research suggests that some ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Medically reviewed by Alicen Nelson, MD, MPH Key Takeaways Early signs of sepsis may include severe pain, shortness of breath, and mental confusion. Sepsis can quickly progress to septic shock and ...

SYDNEY--(BUSINESS WIRE)--Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced an international patent application aimed at protecting the use of experimental ...

The incidence of sepsis (and death from septic shock) is increasing, and treatments are still inadequate. Now a study in Science offers promise for a new treatment option involving blockade of ...

Funding from a U.S.-Israeli fund will support advanced preclinical and Phase I testing. Fast-Track Drugs & Biologics and Atox Bio, a spin-out of the Hebrew University of Jerusalem, won a $575,000 ...

Craig Lilly, MD, a pulmonary medicine and critical care specialist at the University of Massachusetts Memorial Medical Center, who was not one of the trial results authors, reacted to the study. "This ...